# OnCo record delcath (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/delcath/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "delcath" ;
  schema:name "Delcath Systems"@en ;
  schema:alternateName "Delcath"@en, "Delcath Systems, Inc."@en, "melphalan for Injection/Hepatic Delivery System"@en ;
  schema:description "Delcath makes the Hepzato Kit, the melphalan percutaneous hepatic perfusion system approved by the FDA in 2023 for uveal melanoma that has spread to the liver, and sells the same device in Europe as Chemosat."@en ;
  schema:url <https://onco.cc/companies/delcath/>, <https://www.delcath.com/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Delcath_Systems> ;
  owl:sameAs <http://www.wikidata.org/entity/Q5253556> ;
  schema:citation <https://www.delcath.com/>, <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-melphalan-liver-directed-treatment-uveal-melanoma> ;
  onco:tag "fda-oce-applicant" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/uveal-melanoma/> ;
  onco:sections <https://onco.cc/fronts/surgery/>, <https://onco.cc/fronts/chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/hepzato/> ;
  onco:trials <https://onco.cc/trials/nct05022901/>, <https://onco.cc/trials/nct06607458/> .